Endocrine Abstracts

Introduction: Pasireotide sc has a proven favourable efficacy and safety profile in CD patients, as shown in clinical trials. Here, we report safety and efficacy results from an expanded-access study designed to allow CD patients to receive pasireotide until regulatory approval for commercial use and reimbursement was obtained in their country.Methods: Pasireotide-naïve adults with CD (mean 24-hour urinary free cortisol [mUFC; of three samples] exce...

Background: Pasireotide (Signifor®), a multireceptor-targeted somatostatin analogue, was initially approved in Europe and the USA in 2012 for treating adult patients with Cushing’s disease for whom surgery is not an option/has failed. This ‘expanded-access’ study allowed patients to receive pasireotide until regulatory approval was obtained in their country, and collected further safety/efficacy data. Here we report an interim analysis of this on...

Context: Sodium-glucose cotransporter 2 (SGLT2) inhibitors induce glycosuria and improve glycemic control, β cell function and insulin sensitivity in type 2 diabetes mellitus (DM2). On the other hand, these drugs predispose to diabetic ketoacidosis by increasing the tonus of glucagon. Glucagon acts on the liver and has no relevant effect on peripheral lipolysis and release of free fatty acids (FFA) as a substrate for ketogenesis, an action attributed to growth hormone (GH...